Skip to content

To assess the safety of mosquito repellent red coil (metofluthrin) in human volunteers.

A prospective, non-comparative, multi-center, post marketing surveillance study in human volunteers, among inmates of households exposed to 0.005%w/w Metofluthrin Red coil in single zone for duration of one year.

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
CTRI
Registry ID
CTRI/2022/05/042355
Enrollment
120
Registered
2022-05-02
Start date
Unknown
Completion date
Unknown
Last updated
2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: 0.005% w/w Metofluthrin Red coil: 0.005%w/w Red mosquito repellent coil used on daily basis for 12 hours for 365 consecutive nights. Control Intervention1: NA: NA

Sponsors

Ms Sumitomo Chemical India Pvt Ltd
Lead Sponsor
Ross Lifescience PvtLtd
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: 1) Written informed consent from the subject. 2) Age more than 12 years completed.

Exclusion criteria

Exclusion criteria: 1) Subjects with any condition which in the opinion of the investigator makes the subject unsuitable for inclusion. 2) Pregnancy 3) Lactation 4) Chronic respiratory disorder 5) Simultaneous participation in any other trial

Design outcomes

Primary

MeasureTime frame
1) Change from baseline in vital signs. 2) Change from baseline in clinical chemistry, urine analysis and haematology. 3) Adverse events reporting.Timepoint: 90, 180, 365 days

Secondary

MeasureTime frame
NATimepoint: NA

Countries

India

Contacts

Public ContactDr Milan Satia

Ethicare Clinical Trial Service

milansatia@ethicare-cro.com9825585119

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026